GlassScriptPhysician profile
Lindsay Panek
NPI 1578098620
$11,148.96
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,892 · 2022: $2,847 · 2023: $4,121 · 2024: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,318 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,317.70 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,547.91 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $1,131.24 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $926.96 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $915.29 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $754.69 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $660.31 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $649.67 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $632.86 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $614.38 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $394.13 | 2021-2023 | Fanapt, Hetlioz |
| Lundbeck LLC | $377.64 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $265.21 | 2022-2023 | Auvelity |
| Validus Pharmaceuticals LLC | $237.00 | 2021 | |
| Merck Sharp & Dohme LLC | $230.95 | 2021-2023 | Belsomra |
| Bausch Health US, LLC | $225.69 | 2021-2024 | Wellbutrin, Aplenzin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $200.81 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $187.47 | 2021-2024 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $182.80 | 2021-2022 | |
| Eisai INC. | $174.15 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $165.12 | 2021-2022 | |
| Uswm, LLC | $162.64 | 2023 | Lucemyra, Zimhi |
| Indivior INC. | $128.82 | 2021-2023 | Sublocade |
| Almatica Pharma LLC | $125.87 | 2021-2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $110.82 | 2021 | |
| Tris Pharma INC | $67.75 | 2023-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $31.50 | 2021 | |
| Hikma Pharmaceuticals USA | $17.58 | 2022 | |
| Gilead Sciences, INC. | $14.99 | 2021 | |
| Neos Therapeutics, LP | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Panek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.